- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.8 Amendment Agreement Dated December 14, 2006
- 10.25 Separation Agreement Dated November 10, 2006
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 List of Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32 Certification of Annual Financial Report by the Chief Officers
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
NPS Pharmaceuticals, Inc.:
We consent to incorporation by reference in the registration statements (Nos. 33-79622, 333-17521, 333-94269, 333-124821, 333-126817 and 333-126823) on Forms S-8 and (Nos. 333-41758, 333-106770, 333-108612, 333-117219, 333-127756 and 333-131273) on Forms S-3 of NPS Pharmaceuticals, Inc. of our reports dated March 13, 2007, relating to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2006 and 2005, and the related consolidated statements of operations, stockholders’ equity (deficit) and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2006, management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2006 and the effectiveness of internal control over financial reporting as of December 31, 2006, which reports appear in the December 31, 2006 annual report on Form 10-K of NPS Pharmaceuticals, Inc.
Our report refers to a change in the method of accounting for stock-based compensation in 2006.
KPMG
Salt Lake City, Utah
March 13, 2007